Skip to main content
. Author manuscript; available in PMC: 2019 Feb 21.
Published in final edited form as: Vaccine. 2018 Feb 21;36(9):1174–1182. doi: 10.1016/j.vaccine.2018.01.035

Fig. 5. Human monocyte-derived DC respond preferentially to TLR8-specific agonist.

Fig. 5

(a) Human CD14+ monocytes propagated for 7 days as described in Materials and Methods were >95% CD11c+ and had typical veiled morphology of conventional DC after cytocentrifugation and staining with Diff-Quick. Representative dot plots depicting anti-CD11c staining and the isotype control from 1 of 3 donors are shown. (b) On day 7 cells were treated for 24 hrs with 10 μM R848 (TLR7/8 agonist), R837 (TLR7-specific agonist) or TL8-506 (TLR8-specific agonist) and TNFα in supernatants was measured by ELISA. Data from 3 experiments using different donors is shown.